Core Insights - Vivos Therapeutics has achieved 'in-network' status with several major health insurance payers in Nevada, enhancing patient access to its obstructive sleep apnea (OSA) treatments and potentially increasing revenue and profitability [1][2][3][4] - The company is implementing cost reduction initiatives aimed at its legacy business model, which are expected to save approximately $4 million annually, thereby reducing cash burn and moving towards cash flow positivity in fiscal year 2026 [5][12] Insurance Coverage - Vivos' physician-owned practices in Nevada have gained 'in-network' status with multiple health insurance providers, including Medicare, UnitedHealthcare, and Aetna, which cover a significant portion of the Las Vegas metropolitan area population [3][4] - This development is anticipated to improve patient access to Vivos' patented OSA treatments, allowing previously evaluated patients to be contacted regarding insurance coverage availability [4] Cost Reduction Initiatives - The company has initiated a series of cost reduction measures, including workforce reduction and restructuring vendor relationships, to streamline operations related to its legacy dental-focused distribution model [5] - These initiatives are projected to yield around $4 million in annual savings, which will help in reducing the company's cash burn rate [5][12] Market Context - OSA affects over 1 billion people globally, with a significant portion remaining undiagnosed, highlighting the ongoing need for effective treatment solutions [8] - Vivos aims to address the complexities of OSA treatment through innovative technology and collaborations with healthcare providers, moving away from traditional CPAP treatments [9][10]

Core Insights - Alkermes plc announced positive topline results from the Vibrance-2 phase 2 study for alixorexton in narcolepsy type 2, showing significant improvements in excessive daytime sleepiness and sleep latency compared to placebo [1][2][4] Group 1: Study Results - Alixorexton met dual primary endpoints, showing statistically significant improvements on the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) at week eight [2] - The 14 mg and 18 mg doses of alixorexton achieved statistical significance in mean sleep latency improvements compared to placebo [3] - The 18 mg dose also showed statistically significant improvements in excessive daytime sleepiness on the ESS at week eight [4] Group 2: Safety and Tolerability - Alixorexton was generally well tolerated across all doses during the eight-week treatment period, with most treatment-emergent adverse events (TEAEs) being mild to moderate [4] Group 3: Future Plans - Results from Vibrance-2 and the previous Vibrance-1 study support the initiation of a global phase 3 program for alixorexton in patients with narcolepsy type 1 and type 2, planned to start in Q1 2026 [5] - Detailed results, including exploratory patient-reported outcomes related to cognition and fatigue, will be presented at a future scientific meeting [5] Group 4: Ongoing Studies - The Vibrance-3 phase 2 study evaluating alixorexton in adults with idiopathic hypersomnia is currently enrolling [6]